Edgewise Therapeutics, Inc.
EWTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $37,480 | $33,558 | $36,757 | $36,370 |
| G&A Expenses | $9,378 | $9,052 | $9,202 | $9,170 |
| SG&A Expenses | $9,378 | $9,052 | $9,202 | $9,170 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $46,858 | $42,610 | $45,959 | $45,540 |
| Operating Income | -$46,858 | -$42,610 | -$45,959 | -$45,540 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6,192 | $6,495 | $5,161 | $5,878 |
| Pre-Tax Income | -$40,666 | -$36,115 | -$40,798 | -$39,662 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$40,666 | -$36,115 | -$40,798 | -$39,662 |
| % Margin | – | – | – | – |
| EPS | -0.39 | -0.34 | -0.43 | -0.42 |
| % Growth | -14.7% | 20.9% | -2.4% | – |
| EPS Diluted | -0.39 | -0.34 | -0.43 | -0.42 |
| Weighted Avg Shares Out | 105,493 | 104,940 | 95,130 | 92,415 |
| Weighted Avg Shares Out Dil | 105,493 | 104,940 | 95,130 | 92,415 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,192 | $6,495 | $5,161 | $5,878 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $523 | $567 | $554 | $629 |
| EBITDA | -$40,143 | -$42,043 | -$45,405 | -$44,911 |
| % Margin | – | – | – | – |